Lechevallier E
Service d'Urologie, Hôpital Salvator, Marseille, France.
Prog Urol. 1996 Aug-Sep;6(4):507-18.
At the present time, the diagnosis of prostatic cancer is based on prostatic needle biopsy in 90% of cases. Prostatic needle biopsy is classically indicated in the presence of a clinical suspicion of prostatic cancer (digital rectal examination, PSA, ultrasonography, but it can also be indicated for re-evaluation of a first negative biopsy or for stages T1a-b, in the case of prostatic intra-epithelial neoplasia, or in the case of detectable PSA after radical prostatectomy. It must be ultrasound-guided with a sextant, biopsying the suspicious zone. It is associated with a low incidence of minor morbidity. Analysis of the biopsy cores should provide information allowing estimation of the tumour volume and stage. However, despite all of these advantages, the detection rate of prostatic needle biopsy does not ensure detection of all prostatic cancers and cannot distinguish non-significant carcinomas.
目前,90%的前列腺癌诊断基于前列腺穿刺活检。经典情况下,当临床怀疑前列腺癌时(直肠指检、前列腺特异抗原、超声检查),会进行前列腺穿刺活检;但对于首次活检阴性后的重新评估,或T1a - b期、前列腺上皮内瘤变情况,或根治性前列腺切除术后可检测到前列腺特异抗原的情况,也可进行活检。活检必须在超声引导下采用六分区法,对可疑区域进行取材。其轻微并发症发生率较低。对活检组织芯的分析应能提供信息,以便估计肿瘤体积和分期。然而,尽管有这些优点,前列腺穿刺活检的检出率并不能确保检测出所有前列腺癌,也无法区分非显著性癌。